Quick Answer
Dermata Therapeutics, Inc. reported Operating Income Loss of -$7.77 million for the year ending 2025.
- Dermata Therapeutics, Inc. showed an increase of +37.9% in Operating Income Loss from 2024 to 2025.
- This data is from Dermata Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$792.8 thousand | Q3 2020: -$540.1 thousand | Q1 2021: -$2.26 million | Q2 2021: -$1.33 million | Q3 2021: -$1.71 million | Q1 2022: -$2.79 million | Q2 2022: -$2.73 million | Q3 2022: -$2.45 million | Q1 2023: -$2.28 million | Q2 2023: -$1.73 million | Q3 2023: -$1.81 million | Q1 2024: -$3.20 million | Q2 2024: -$2.88 million | Q3 2024: -$3.23 million | Q1 2025: -$2.34 million | Q2 2025: -$1.77 million | Q3 2025: -$1.76 million.
- Over the full 6 years of available data (2020 to 2025), Dermata Therapeutics, Inc.'s Operating Income Loss has declined by 145.0%.
- Historical annual values: Fiscal year 2025: -$7.77 million | Fiscal year 2024: -$12.51 million | Fiscal year 2023: -$8.04 million | Fiscal year 2022: -$9.67 million | Fiscal year 2021: -$7.86 million | Fiscal year 2020: -$3.17 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: